Our ethos, values and culture
About us
Avanzanite is redefining launches of rare disease medicines across Europe.
Founded in 2022 and based in Amsterdam, we partner with biotech innovators to unlock the full commercial value of orphan medicines across the continent.
Our deep expertise in market access allows us to navigate Europe’s complex landscape with precision and purpose, ensuring no patient battling a rare disease is left behind.
-
Partnering with emerging biotech companies
We collaborate closely with emerging biotech firms to accelerate the commercialisation and distribution of their orphan medicines across all European markets.
Like skilled chess players, we decode complex market access challenges and make strategic moves that unlock potential and drive success for our partners.
-
Where potential begins
We see limitless potential in rare disease treatment across Europe. Imagine unlocking that energy—transforming lives, overcoming challenges, and reshaping futures for those who need it most.
Our journey is dedicated to realising this potential and making a tangible difference.
Our Business Model: Making the impossible, possible
Avanzanite acquires, licenses or distributes approved or late-stage medicines for rare diseases and commercialises them everywhere in Europe.
Even in countries where nobody else will.
We do this because far too many patients are waiting and left behind, just because of where they live. That’s not right and not fair.
Nobody should be left behind.
That’s why we founded Avanzanite Bioscience.
Avanzanite is capable of unlocking the full value of medicines for orphan diseases in European markets thanks to its unique skills in identifying market potential and solving the difficult patient access puzzle across Europe. Simply put, we succeed where others often do not even try.
Origin story
Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond.
Derived from the word ‘Tanzanite’
One of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic and one humanitarian.
The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area.
Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Our ethos – nobody should be left behind.
-
Meet the minds behind the mission
Get to know the people driving progress at Avanzanite.
-
It’s not just what we do - it’s how
Discover the values and culture that drive our work and define who we are.